This inventor holds 6 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Regulus Therapeutics Inc.. Active years: 2010-2015.
Company Filing History:
Years Active: 2010-2015
Title: The Innovative Contributions of Bridget Lollo
Introduction
Bridget Lollo is a prominent inventor based in Encinitas, California. She has made significant contributions to the field of biotechnology, particularly in the modulation of small non-coding RNAs. With a total of 6 patents to her name, Lollo's work has the potential to impact various medical applications.
Latest Patents
One of her latest patents is titled "Oligomeric compounds and compositions for use in modulation of small non-coding RNAs." This patent provides compounds, compositions, and methods for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs. Additionally, methods for using these compounds for modulation of small non-coding RNAs, as well as downstream targets of these RNAs, are included for the diagnosis and treatment of diseases associated with small non-coding RNAs. Another significant patent is "Method of inhibiting miR-33 using a modified oligonucleotide," which also focuses on modulating the expression and function of small non-coding RNAs.
Career Highlights
Bridget Lollo is currently associated with Regulus Therapeutics Inc., where she continues to advance her research and innovations. Her work has garnered attention in the scientific community, contributing to the understanding of RNA modulation and its implications in health and disease.
Collaborations
Some of her notable coworkers include Ravi Jain and C. Frank Bennett, who collaborate with her on various projects within the field of biotechnology.
Conclusion
Bridget Lollo's innovative work in the modulation of small non-coding RNAs showcases her dedication to advancing biotechnology. Her patents reflect her commitment to developing methods that could lead to significant medical breakthroughs.